Zentalis Pharmaceuticals, Inc. (ZNTL) Return on equity 2022–2025
Zentalis Pharmaceuticals, Inc. (ZNTL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-63.4%FY2025 · since FY2022: -54.6% → -63.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -63.4% | -14.2 pp |
| FY2024 | -49.2% | +17.7 pp |
| FY2023 | -66.8% | -12.3 pp |
| FY2022 | -54.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice